1 videos available from ENDO
ENDO 2026 POST CONFERENCE HIGHLIGHTS
Endo 2026 Post Conference Updates feature expert commentary and discussion led by Zehra Tekin, MD, Felona Gunawan, MD, and Sadia Ali, MD. This program highlights key clinical and scientific advances presented at ENDO 2026, focusing on the latest research, evidence-based management strategies, and emerging therapies across the spectrum of endocrinology, diabetes, metabolism, and hormone-related disorders. The session provides in-depth analysis of late-breaking abstracts, landmark clinical trial updates, and evolving treatment approaches, with faculty drawing on their expertise to contextualize these findings for clinical practice. Attendees gain an understanding of emerging standards of care, innovative therapeutic developments, and important areas of ongoing research presented at ENDO 2026. Through expert discussion and practical clinical perspectives, ENDO 2026 Post Conference Highlights serves as a concise, high-yield review for clinicians, trainees, and researchers seeking to incorporate the most impactful discoveries from ENDO 2026 into their clinical practice and scholarly activities.
Key Learning Points:
- Tirzepatide's Effect on BAT: Tirzepatide not only suppresses appetite but also increases brown adipose tissue (BAT) activity, promoting energy expenditure even during significant weight loss.
- GLP-1 Discontinuation & Cost: Over half of type 2 diabetes patients stop GLP-1 therapy within two years. This high discontinuation rate is driven primarily by cost and insurance barriers, rather than medication side effects.
- PRRT for Rare Adrenal Tumors: Targeted Lutetium-177 therapy successfully controlled the disease in 83% of patients with severe, inoperable pheochromocytomas and paragangliomas without triggering dangerous catecholamine crises.
- +2 more points...